Patent US4642111A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4642111A Expired / Lapsed US ⏱️ 0.0 years remaining

Injector filled with an anti-cancer composition

Assignee: Unitika Ltd
•
Filing: 1985-03-13
•
Granted: 1987-02-10
•
Expires: 2005-03-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An anti-cancer device having an anti-cancer drug and a blood coagulation factor fixed to a structure. This anti-cancer device is used in transcatheter arterial embolization and needle therapy with advantage and slowly releases the anti-cancer drug over an extended period by staying in the cancer tissue and its nearby area.

Inventors

  • 👤 Izumi Sakamoto
  • 👤 Kunihiko Takagi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 18:37
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/56; A61K47/59; A61K47/595; A61K47/61

Claims Analysis

Total Claims: 55
Claim 1
Independent Claim 69 words
An injector filled with a composition comprising: (a) a polymer, wherein said polymer has fixed thereto; (b) an anti-cancer drug; and (c) a blood coagulation factor, wherein said anti-cancer drug and said blood coagulation factor are fixed to said polymer so as to be capable of sustained release from the polymer at the site of injection and wherein said composition is useful for transcatheter arterial embolization and needle therapy.
Claim 2
Dependent Claim 69 words
An injector filled with a composition comprising: (a) a polymer, wherein said polymer has fixed thereto; (b) an anti-cancer drug; and (c) a blood coagulation factor, wherein said anti-cancer drug and said blood coagulation factor are fixed to said polymer so as to be capable of sustained release from the polymer at the site of injection and wherein said composition is useful for transcatheter arterial embolization and needle therapy.
Claim 3
Dependent Claim 14 words
The injector as claimed in claim 1, wherein said polymer is a synthetic polymer.
Claim 4
Dependent Claim 13 words
The injector as claimed in claim 2, wherein said synthetic polymer is silicone.
Claim 5
Dependent Claim 25 words
The injector as claimed in claim 1, wherein said polymer is selected from the group consisting of cellulosic material, cellulosic material derivative and regnerated cellulose.
Claim 6
Dependent Claim 15 words
The injector as claimed in claim 4, wherein said cellulosic material derivative is ethyl cellulose.
Claim 7
Dependent Claim 13 words
The injector as claimed in claim 1, wherein said polymer is bioabsorable material.
Claim 8
Dependent Claim 13 words
The injector as claimed in claim 6, wherein said bioabsorable material is polysaccharide.
Claim 9
Dependent Claim 12 words
The injector as claimed in claim 7, wherein said polysaccharide is amylose.
Claim 10
Dependent Claim 13 words
The injector as claimed in claim 7, wherein said polysaccharide is oxidized cellulose.
Claim 11
Dependent Claim 12 words
The injector as claimed in claim 7, wherein said polysaccharide is chitin.
Claim 12
Dependent Claim 13 words
The injector as claimed in claim 6, wherein said bioabsorable material is collagen.
Claim 13
Dependent Claim 13 words
The injector as claimed in claim 6, wherein said bioabsorable material is gelatin.
Claim 14
Dependent Claim 14 words
The injector as calimed in claim 6, wherein said bioabsorable material is polyamino acid.
Claim 15
Dependent Claim 14 words
The injector as claimed in claim 13, wherein said polyamino acid is polyglycolic acid.
Claim 16
Dependent Claim 14 words
The injector as claimed in claim 13, wherein said polyamino acid is polylactic acid.
Claim 17
Dependent Claim 18 words
The injector as claimed in claim 1, wherein the polymer is in the form of a fibrous assembly.
Claim 18
Dependent Claim 18 words
The injector as claimed in claim 16, wherein said fibrous assembly is an assembly of oxidized cellulose fiber.
Claim 19
Dependent Claim 17 words
The injector as claimed in claim 16, wherein said fibrous assembly is an assembly of gelatin fiber.
Claim 20
Dependent Claim 17 words
The injector as claimed in claim 16, wherein said fibrous assembly is an assembly of chitin fiber.
Claim 21
Dependent Claim 17 words
The injector as claimed in claim 1, wherein said polymer is in the form of a sponge.
Claim 22
Dependent Claim 14 words
The injector as claimed in claim 20, wherein said sponge is oxidized cellulose sponge.
Claim 23
Dependent Claim 13 words
The injector as claimed in claim 20, wherein said sponge is gelatin sponge.
Claim 24
Dependent Claim 13 words
The injector as claimed in claim 20, wherein said sponge is chitin sponge.
Claim 25
Dependent Claim 17 words
The injector as claimed in claim 1, wherein said polymer is in the form of a powder.
Claim 26
Dependent Claim 14 words
The injector as claimed in claim 24, wherein said powder is oxidized cellulose powder.
Claim 27
Dependent Claim 13 words
The injector as claimed in claim 24, wherein said powder is gelatin powder.
Claim 28
Dependent Claim 13 words
The injector as claimed in claim 24, wherein said powder is chitin powder.
Claim 29
Dependent Claim 17 words
The injector as claimed in claim 1, wherein said polymer is in the form of a monofilament.
Claim 30
Dependent Claim 17 words
The injector as claimed in claim 1, wherein said polymer is in the form of a film.
Claim 31
Dependent Claim 17 words
The injector as claimed in claim 1, wherein said polymer is in the form of a microcapsule.
Claim 32
Dependent Claim 15 words
The injector as claimed in claim 1, wherein said anti-cancer drug is an alkylating agent.
Claim 33
Dependent Claim 19 words
The injector as claimed in claim 1, wherein said anti-cancer drug is a combination of cyclophosphamide, 5-fluorouracil and mitomycin.
Claim 34
Dependent Claim 19 words
The injector as claimed in claim 1, wherein said anti-cancer drug is a combination of cyclophosphamide, 5-fluorouracil and bleomycin.
Claim 35
Dependent Claim 13 words
The injector as claimed in claim 1, wherein said anto-cancer drug is bleomycin.
Claim 36
Dependent Claim 14 words
The injector as claimed in claim 1, wherein said antic-cancer drug is mitomycin C.
Claim 37
Dependent Claim 13 words
The injector as claimed in claim 1, wherein said anti-cancer drug is adriamycin.
Claim 38
Dependent Claim 13 words
The injector as claimed in claim 1, wherein said anti-cancer drug is 5-fluorouracil.
Claim 39
Dependent Claim 15 words
The injector as claimed in claim 1, wherein said blood coagulation factor is Factor XIII.
Claim 40
Dependent Claim 14 words
The injector as claimed in claim 1, wherein said blood coagulation factor is thrombin.
Claim 41
Dependent Claim 20 words
The injector as claimed in claim 1, wherein said blood coagulation factor is a combination of Factor XIII and thrombin.
Claim 42
Dependent Claim 26 words
The injector as claimed in claim 1, wherein said anti-cancer drug and blood coagulation factor are fixed to the polymer by covalently bonding to the polymer.
Claim 43
Dependent Claim 16 words
The injector as claimed in claim 1, wherein calcium ion is additionally fixed to said polymer.
Claim 44
Dependent Claim 16 words
The injector as claimed in claim 1, wherein a pharmaceutical is additionally fixed to said polymer.
Claim 45
Dependent Claim 27 words
The injector as claimed in claim 43, wherein said pharmaceutical is selected from the group consisting of protease inhibitors, plasma proteins, fibronectin, antiboitics, antivirals, sulfanamides and anti-infectives.
Claim 46
Dependent Claim 26 words
The injector as claimed in claim 1, wherein said polymer is a bioabsorable polymer and wherein said polymer is in the form of a fibrous assembly.
Claim 47
Dependent Claim 25 words
The injector as claimed in claim 1, wherein said polymer is a bioabsorable material and wherein said polymer is in the form of a sponge.
Claim 48
Dependent Claim 25 words
The injector as claimed in claim 1, wherein said polymer is a bioabsorable material and wherein said polymer is in the form of a powder.
Claim 49
Dependent Claim 25 words
The injector as claimed in claim 1, wherein said polymer is a bioabsorable material and wherein said polymer is in the form of a monofilament.
Claim 50
Dependent Claim 25 words
The injector as claimed in claim 1, wherein said polymer is a bioabsorable material and wherein said polymer is in the form of a film.
Claim 51
Dependent Claim 24 words
The injector as claimed in claim 1, wherein said polymer is bioabsorable material and wherein said polymer is in the form of a microcapsule.
Claim 52
Dependent Claim 52 words
The injector as claimed in claim 1, wherein said polymer is gelatin powder, said anti-cancer drug, and said blood coagulation factor are fixed to said polymer by ionic bonding, entrapping and adsorption, said anti-cancer drug is mitomycin C and wherein said blood coagulation factor is a combination of Factor XIII and thrombin.
Claim 53
Dependent Claim 40 words
The injector as claimed in claims 1, 6, 16, 20, 24, 28, 29, 30, 45, 46, 47, 48, 49 or 50, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer by ionically bonding to said polymer.
Claim 54
Dependent Claim 36 words
The injector as claimed in claims 1, 6, 16, 20, 24, 28, 29, 30, 45, 46, 47, 48, 49 or 50, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer, by adsorption.
Claim 55
Dependent Claim 36 words
The injector as claimed in claims 1, 6, 16, 20, 24, 28, 29, 30, 45, 46, 47, 48, 49 or 50, wherein said anti-cancer drug and blood coagulation factor are fixed to said polymer by entrapping.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-02-09 1990-08-11 1991-02-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-02-09 1994-08-11 1995-02-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-02-09 1998-08-11 1999-02-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag